peficitinib + tacrolimus

**peficitinib + tacrolimus** is a combination of two immunosuppressive agents. Peficitinib (ASP015K, JNJ-54781532) is an oral Janus kinase (JAK) inhibitor with moderate selectivity for JAK3 over JAK1 and JAK2, developed primarily for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Its mechanism is to block JAK-mediated cytokine signaling, particularly in T cells[2][4][6][8]. Tacrolimus (also known as FK-506, fujimycin) is a macrolide immunosuppressant that acts as a calcineurin inhibitor by binding to FKBP12, which in turn inhibits T-cell signal transduction and IL-2 transcription, thus reducing T-cell proliferation[1][5][7]. In clinical practice, tacrolimus is a mainstay for prevention of organ rejection after transplantation and is used off-label for autoimmune diseases. The specific oral combination "peficitinib + tacrolimus" does not appear as a marketed fixed-dose product but has likely been studied for potential pharmacokinetic or immunosuppressive interactions.

Brand names

AstagrafModigrafTacforius

Other names

peficitinibtacrolimus